Mesothelioma is a rare cancer affecting only about 3,000 Americans each year. Most of those diagnosed are diagnosed with pleural mesothelioma, but a small number (approx. 500 per year) are diagnosed with peritoneal mesothelioma, which is mesothelioma in the abdominal lining. With so few diagnosed with peritoneal mesothelioma, studying and[…]
Overall Survival
Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results
Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]
Survival Improves in Mesothelioma Patients who Received an Electricity-Based Treatment
The success of a recent Phase II clinical trial in malignant pleural mesothelioma has scientists and researchers excited about the possibility of adding a new treatment that will not only improve survival, but also improve quality of life of the cancer patient. Tumor Treating Fields, which is a therapy that[…]
Decrease in Survival Rate Among Those Who Receive Non-traditional Cancer Treatment
Complementary medicine and alternative medicine may sound one in the same, but are vastly different in how each is used, and varying results often make people wary of its true effectiveness. Alternative medicine is atypical, and not used with any sort of mainstream treatment. Complementary medicine, sometimes referred to as[…]
Potential Breakthrough in Immunotherapy after Nivolumab Study Results
Immunotherapy treatments have once again made headlines, revolutionizing modern medicine and the way we have come to understand cancer treatment. The latest study results published in the American Journal of Case Reports, focuses on Opdivo (nivolumab), a type of check point inhibitor designed to stop immune cells from attacking the[…]
Why is Chemotherapy Often Ineffective in Those Suffering from Mesothelioma?
Mesothelioma is a difficult cancer to treat for a multitude of reasons. A mesothelioma diagnosis is rare – only about 3,000 people per year in the United States are diagnosed – and this can make it difficult to study, given that there is generally a very small sample of patients[…]
Updated Modified RECIST to Better Evaluate Treatment Response in Mesothelioma
The Response Evaluation Criteria in Solid Tumors (RECIST) was established nearly two decades ago by the European Organization for Research and Treatment of Cancer and the National Cancer Institute of the United States. The purpose of these published rules was to universally define when cancerous tumors stabilize, progress, or just[…]
Immunotherapy – What Side Effects Can You Expect?
As the success of immunotherapy treatments in improving survival and symptom management for cancer patients have started to become known, those suffering from cancer such as mesothelioma and lung cancer may now be given options in terms of the best course of treatment. Immunotherapy works with the body’s own natural[…]
Aerosol Chemotherapy – Targeting Peritoneal Mesothelioma Through Pressurized Medicine
Peritoneal mesothelioma is an incredibly rare form of cancer that affects the peritoneum, or abdominal lining. It is not entirely understood how exposure to asbestos causes this type of cancer, but scientists and researchers theorize that ingested asbestos fibers work themselves into the peritoneal cavity, or if inhaled, are transported[…]
New Surgical Technique Could Be Ideal for Patients with Advanced Pleural Mesothelioma
Pleural mesothelioma is a rare and aggressive cancer that has been notoriously difficult to treat. Caused by asbestos exposure, the latency period between the time of initial exposure and disease spans decades and generally by the time the cancer is detected, it is highly advanced. Surgical treatments for those with[…]
Skip to content